Results 31 to 40 of about 1,008 (88)

Investigation of iterative deconvolution in ¹⁷⁷Lu-SPECT imaging for lesion dosimetry. [PDF]

EJNMMI Phys
Ells Z, Liubchenko G, Rumiantcev M, Scheifele M, Noto A, Siegmund SC, Resch S, Harbach A, Werner RA, Brendel M, Sheikh G, Zacherl M, Böning G, Unterrainer LM, Ziegler SI, Delker A.   +15 more
europepmc   +1 more source

[¹⁷⁷Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2-3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial. [PDF]

EClinicalMedicine
Ferone D, Pavel M, Herrmann K, Kunz PL, Myrehaug S, Halperin D, Chasen B, Capdevila J, García-Burillo A, Tafuto S, Lastoria S, Oh DY, Yoo C, Falk S, Halfdanarson TR, Sansovini M, Gerard L, Deshayes E, Filice A, Folitar I, Zhang Y, de Herder WW, Singh S.   +22 more
europepmc   +1 more source

Combination therapy strategies in engineered ¹⁷⁷Lu radiopharmaceuticals beyond single modality: design principles and application outlet. [PDF]

Cell Commun Signal
Zhu Y, Zhong G, Zhang W, Wei W, Yin B, Zhang K.   +5 more
europepmc   +1 more source

Palladium-103 as a Theranostic Auger Electron Emitter: From Cyclotron Production to Preclinical SPECT Evaluation in Murine and Canine Models. [PDF]

Pharmaceuticals (Basel)
Laouameria AN, Máthé D, Kubovje A, Vajdovich P, Balka G, Hunyadi M, Bergmann RK, Halldin C, Forgách L, Horváth I, Szigeti K, Psáder R, Zeevaart JR, Csige L, Szűcs Z.   +14 more
europepmc   +1 more source

[¹⁷⁷Lu]Lu-DOTA-TATE tumour and organ time-activity curves: prediction from a single-time-point [⁶⁸Ga]Ga-DOTA-TATE PET/CT measurement. [PDF]

EJNMMI Phys
Vasić V, Gustafsson J, Yousefzadeh-Nowshahr E, Beer AJ, Sjögreen Gleisner K, Glatting G.   +5 more
europepmc   +1 more source

Morphological versus spherical cellular geometry models: impact on dose-response of CA20948 cells to ¹⁷⁷Lu- and ¹⁶¹Tb-labeled DOTA-TATE and DOTA-LM3. [PDF]

EJNMMI Phys
Spoormans K, Crabbé M, Struelens L, Koole M.   +3 more
europepmc   +1 more source

Clinical Outcomes of Peptide Receptor Radionuclide Therapy in Japanese Patients with Metastatic Rectal Neuroendocrine Tumors. [PDF]

Cancers (Basel)
Iizuka T, Kobayashi N, Wild D, Kaul F, Suzuki H, Maehara K, Okubo N, Tsuyuki S, Takano S, Kurita Y, Yoneda M, Ichikawa Y.   +11 more
europepmc   +1 more source

Radiopharmaceutical: An Update and Comparison of Preclinical Investigation Result of Alpha and Beta Emitter Radioisotope. [PDF]

Drug Des Devel Ther
Luhung A, Hasanah AN, Ramdhani D.
europepmc   +1 more source

Peptide Nucleic Acid Probes for Pretargeted Affibody-Mediated Delivery of Cytotoxic Payloads to HER2-Positive Carcinoma. [PDF]

Bioconjug Chem
Clinton J, Westerlund K, Haraldsson A, Nordén E, Hagelin T, Papalanis E, Ud-Din M, Vorobyeva A, Gräslund T, Eriksson Karlström A, Oroujeni M.   +10 more
europepmc   +1 more source

Cellular responses to targeted radionuclide therapy: rethinking radiobiology under continuous low dose rates. [PDF]

Front Oncol
Engbers PAM, Nonnekens J, Sabatella M.
europepmc   +1 more source